Table 2.
Breakdown of data by clinical site.
| Site | Country | Number of completed questionnaire responses | Number of patient responders | Number of questionnaires not completed | Questionnaire schedule | Location of questionnaire completion | Site response rate (%) | Consent process for questionnaires | Comments |
|---|---|---|---|---|---|---|---|---|---|
| 1 | UK | 35 | 10 | 3 | First 3 and final fractions (4 per patient) | Immediately after treatment | 92 | Included within a feasibility trial | Two patients received only three treatments and therefore were not given a fourth questionnaire |
| 2 | UK | 12 | 6 | 0 | First and final fractions (2 per patient) | Immediately after treatment | 100 | Included within a feasibility trial | |
| 3 | Germany | 103 | 99 | 10 | Weekly, least favourable response included (1 per patient) | Immediately after treatment | 91 | Included within a feasibility trial | Four patients received two separate treatment courses and therefore contributed two responses each |
| 4 | Denmark | 10 | 10 | 0 | Final fraction | Immediately after treatment | 100 | Included within a feasibility trial | |
| 5 | USA | 10 | 10 | 0 | Once during the treatment course | At home | 100 | IRB waiver acquired retrospectively |